InsiderTradr

CelLBxHealth plc (CLBX.L)

LSE · GBp · Healthcare · Diagnostics & Research

£0.58 (-3.33%) as of

Key statistics

Market cap
6.59M
Forward P/E
-3.31
EPS (TTM)
-0.0300
Dividend yield
0.00%
52-week range
0.5330 – 2.8990
Beta
0.60
Revenue (TTM)
1.15M
Profit margin
0.00%
Analyst target
£3.00
Volume
385.94k

About CelLBxHealth plc

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Sector
Healthcare
Industry
Diagnostics & Research
Headquarters
Guildford, United Kingdom
Employees
114

cellbxhealth.com

Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.

Related stocks